Ergonomic Recommendations in Ultrasound-Guided Botulinum Neurotoxin Chemodenervation for Spasticity: An International Expert Group Opinion

Philippe Lagnau, Rajiv Reebye(University of British Columbia), Omar Khan(Hotel Dieu Shaver Health and Rehabilitation Centre), Alessandro Picelli(University of Verona), Monica Verduzco‐Gutierrez(The University of Texas Health Science Center at San Antonio), Serdar Koçer(School of the Art Institute of Chicago), Jörg Wissel(University of Potsdam), Areerat Suputtitada(Harvard University), Ryan Sandarage(University of British Columbia), Katharine E. Alter(National Institutes of Health Clinical Center), Alto Lo(University of Alberta), Michael C. Munin(University of Pittsburgh), Stefano Carda(University Hospital of Lausanne)
Toxins
March 31, 2021
10.3390/toxins13040249
Cited by 20

Related Papers

Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation
|Parkinson s Disease|2016|374
Virtual Reality Telerehabilitation for Postural Instability in Parkinson’s Disease: A Multicenter, Single-Blind, Randomized, Controlled Trial
|BioMed Research International|2017|325
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke
|Stroke|2000|298
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport 
|Journal of Neurology Neurosurgery & Psychiatry|1998|219
Introduction and Methodology: <i>Standards of Care in Diabetes—2024</i>
|Diabetes Care|2023|184